"The Impact of ´Long Covid´ on Cardiovascular Disease – BigData@Heart" webinar on November 24th, 2020
Cardiovascular disease appears to play a prominent role in the COVID-19 pandemic. Patients with cardiovascular risk factors and pre-existent cardiovascular disease seem to have an increased risk of a poor outcome and patients with COVID-19 have, in the absence of underlying cardiovascular disease, been reported to develop cardiovascular and thrombotic complications.
Sufficient evidence is currently not available to guide clinicians in the management of these patients and to accelerate knowledge on the role of cardiovascular disease in the COVID-19 pandemic, standardised and coordinated data collection on a large scale is of pivotal importance. Several initiatives were launched during the pandemic to investigate these risks and the impact of COVID-19 on cardiovascular patients and the development of cardiovascular complications due to COVID-19 infection.
BigData@Heart has invited some of these initiatives to share and discuss their results and to exchange best practices during this webinar.
Register here: https://us02web.zoom.us/webinar/register/WN_7RRoDErqR82Feot8nFzwdg
CAPACITY is a registry of patients with COVID-19 and has been established to answer questions on the role of cardiovascular disease in this pandemic. It is an extension of the Case Record Form (CRF) that was released by the ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) and WHO (World Health Organization) in response to the emerging outbreak of COVID-19.
The aim of CAPACITY is to collect data regarding the cardiovascular history, diagnostic information and occurrence of cardiovascular complications in COVID-19 patients. By collecting this information in a standardized manner, CAPACITY can aid in providing more insight in (1) the incidence of cardiovascular complications in patients with COVID-19, and (2) the vulnerability and clinical course of COVID-19 in patients with an underlying cardiovascular disease.
OurRisk.CoV is a public-facing tool being developed to help patients, members of the public, researchers and policymakers to understand their individual risk of dying during the pandemic. It will provide information specific to an individual’s sex, age and underlying conditions.
In March, the UK government announced a list of vulnerable conditions which increased the risk of severe coronavirus infection, and a UCL team began working with patients and members of the public to develop a tool to help provide personalized mortality risk information to inform decisions during the pandemic, whether regarding social isolation, use of public transport or returning to work. A prototype risk calculator was released in May and through an iterative process of continuous patient and public involvement and engagement, a final version is in development with planned release in October 2020.
Read the Lancet article here.
COVID Red: A wearable to spot early COVID-19 cases
In this project, we are evaluating the use and performance of a CE-marked device (wearable), which uses sensors to measure breathing rate, pulse rate, skin temperature, and heart rate variability in combination with a mobile device app that tracks participant-reported symptoms to detect and monitor COVID-19 in general and high-risk populations.
The prospective, observational study will follow 30,000 individuals from the general population and 10,000 high-risk individuals in the Netherlands. Based on this data, an algorithm will indicate which individuals should report for COVID-19 diagnostic testing. To evaluate algorithm performance, the cohort will be tested for COVID-19 antibodies at the end of follow-up.
This registry, sponsored by the American Heart Association, aims to collect consecutive patient data from hospitalized patients with COVID-19, including those with and without cardiovascular disease. The registry leverages the infrastructure of the expansive AHA Get with the Guidelines series of quality improvement registries. The registry includes over 10,000 patients from over 100 U.S hospitals to date. Detailed data on cardiovascular risk factors and cardiac and non-cardiac comorbidities are collected, as are baseline medication and COVID-19 specific therapies. In addition to collection of death, ventilation and ICU stay, comprehensive cardiac outcomes are registered. The registry is piloting a “burst science” approach to discovery, which allows multiple investigative teams to conduct research in parallel on the approved de-identified dataset within the AHA’s Precision Medicine Platform.
24 November 2020, 14.30h – 15.30h CET
Professor of Cardiovascular Genetics, Consultant Cardiologist at the University Medical Center Utrecht
Professor of Precision medicine at the University College London
BigData@Heart Scientific Coordinator
Associate Professor in Clinical Data Science and Honorary Consultant Cardiologist at the University College London Hospitals and Barts Health NHS Trusts
Professor of Clinical Epidemiology at the University Medical Center Utrecht
BigData@Heart Project Coordinator
Former Head of Global Medical Affairs at Vifor Pharma
Professor of Internal Medicine in the Division of Cardiology at UT Southwestern Medical Center
Moderator: Mr Duane Schulthess, MBA, Managing Director, Vital Transformation